Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-555-1 | CAS number: 122-57-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- experimental starting date: 2012-03-28, experimental completion date: 2012-05-31
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- yes
- Remarks:
- The relative humidity in the animal rooms ranged between 35 – 65% instead of 45 – 65%. This deviation, however, does not affect the validity of the study.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- yes
- Remarks:
- The relative humidity in the animal rooms ranged between 35 – 65% instead of 45 – 65%. This deviation, however, does not affect the validity of the study.
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Hess. Ministerium für Umwelt, Energie, Landwirtschaft und Verbraucherschutz, Wiesbaden, Germany
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- 4-phenylbutenone
- EC Number:
- 204-555-1
- EC Name:
- 4-phenylbutenone
- Cas Number:
- 122-57-6
- Molecular formula:
- C10H10O
- IUPAC Name:
- 4-phenylbut-3-en-2-one
- Test material form:
- other: solid
- Details on test material:
- - Name of test material (as cited in study report): 4-phenylbutenone
- Substance type: organic
- Physical state: solid
- Analytical purity: > 98.0 % (dose calculation was not adjusted to purity)
- Storage condition of test material: at room temperature
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Pre-experiment: Harlan Laboratories B.V., Horst / The Netherlands
Main experiment: Charles River Laboratories, Research Models and Services Germany GmbH, Sulzfeld, Germany
- Number of Animals used: 42
- Age at study initiation: 8 - 9 weeks
- Weight at study initiation: mean value 35.0 g (SD +/- 1.7 g)
- Assigned to test groups randomly: [yes]
- Housing: single
- Diet (e.g. ad libitum): ad libitum (pelleted standard diet)
- Water (e.g. ad libitum): ad libitum (tap water)
- Acclimation period: minimum 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2 °C
- Humidity (%): 35 - 65 %
- Photoperiod (hrs dark / hrs light): artificial light 6.00 a.m. - 6.00 p.m.
According to the suppliers assurance the animals were in healthy condition. The animals were under acclimation in the animal house of Harlan CCR for a minimum of five days after their arrival. During this period the animals did not show any signs of illness or altered behaviour.
The animals were distributed into the test groups at random and identified by cage number.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: DMSO; polyethylene glycol
- Justification for choice of solvent/vehicle: The vehicle was chosen to its relative non-toxicity for the animals.
- Concentration of test material in vehicle: On the day of the experiment, the test item was dissolved in 30% DMSO and 70% PEG 400.
- Amount of vehicle (if gavage or dermal): All animals received a single standard volume of 10 mL/kg body weight orally. - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: On the day of the experiment, the test item was dissolved in 30% DMSO and 70% PEG 400. All animals received a single standard volume of 10 mL/kg body weight orally.
- Duration of treatment / exposure:
- once orally (Amount given: 10 mL/ kg bw)
- Frequency of treatment:
- once
- Post exposure period:
- 24 or 48 hours, respectively
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0 mg/kg bw
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
500 mg/kg bw
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
1000 mg/kg bw
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
2000 mg/kg bw
Basis:
nominal conc.
- No. of animals per sex per dose:
- 7 males/ dose
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- cyclophosphamide
- Route of administration: orally once
- Doses / concentrations: 40 mg/kg b.w. (Amount given: 10 mL/kg b.w.)
- Other: The stability of CPA at room temperature was sufficient. At 25 °C only 3.5 % of its potency is lost after 24 hours.
Examinations
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
It is generally recommended to use the maximum tolerated dose or the highest dose that can be formulated and administered reproducibly or 2000 mg/kg as the upper limit for non-toxic test items.
The maximum tolerated dose level is determined to be the dose that causes toxic reactions without having major effects on survival within 48 hours.
The administered volume was 10 mL/kg b.w..
Three adequately spaced dose levels spaced by a factor of 2 were administered, and samples were collected at the central sampling interval 24 h after treatment. For the highest dose level an additional sample was taken at 48 h after treatment.
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields): Sampling of the bone marrow was done 24 and 48 hours after treatment, respectively. The animals were sacrificed using CO2 followed by bleeding. The femora were removed, the epiphyses were cut off and the marrow was flushed out with foetal calf serum using a syringe.
DETAILS OF SLIDE PREPARATION:
The cell suspension was centrifuged at 1500 rpm (390 x g) for 10 minutes and the supernatant was discarded. A small drop of the re-suspended cell pellet was spread on a slide. The smear was air-dried and then stained with May-Grünwald /Giemsa. Cover slips were mounted with EUKITT. At least one slide was made from each bone marrow sample.
METHOD OF ANALYSIS:
Evaluation of the slides was performed using NIKON microscopes with 100x oil immersion objectives. At least 2000 polychromatic erythrocytes (PCE) were analysed per animal for micronuclei. To describe a cytotoxic effect the ratio between polychromatic and normochromatic erythrocytes was determined in the same sample and expressed in polychromatic erythrocytes per 2000 erythrocytes. The analysis was performed with coded slides. - Evaluation criteria:
- The study is considered valid if the following criteria are met:
- at least 5 animals per group can be evaluated.
- PCE to erythrocyte ratio should not be less than 20 % of the negative control.
- the positive control shows a statistically significant and biological relevant increase of micronucleated PCEs compared to the negative control.
Evaluation of Results
A test item is classified as mutagenic if it induces either a dose-related increase or a clear increase in the number of micronucleated polychromatic erythrocytes in a single dose group in comparison to the laboratory’s historical data range. Statistical methods (nonparametric Mann-Whitney test (8)) will be used as an aid in evaluating the results. However, the primary point of consideration is the biological relevance of the results.
A test item that fails to produce a biological relevant increase in the number of micronucleated polychromatic erythrocytes is considered non-mutagenic in this system. - Statistics:
- Statistical significance at the five per cent level (p < 0.05) was evaluated by means of the non-parametric Mann-Whitney test.
Results and discussion
Test results
- Key result
- Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range: 1000 mg/kg bw
- Solubility: test item was dissolved in 30 % DMSO / 70 % PEG 400
- Clinical signs of toxicity in test animals: none (no ruffled fur, no reduction of spontaneous activity
RESULTS OF DEFINITIVE STUDY
- Induction of micronuclei (for Micronucleus assay): no
- Ratio of PCE/NCE (for Micronucleus assay): test item PCE with micronuclei: 0.042 versus 0.05 % in the vehicle control
Any other information on results incl. tables
Pre-Experiment on Toxicity
A preliminary study on acute toxicity was performed with two animals per sex under identical conditions as in the mutagenicity study concerning: animal strain, vehicle, route, frequency, and volume of administration.
The animals were treated once orally with the test item and examined for acute toxic symptoms at intervals of approximately 1 h, 2-4 h, 6 h, 24 h, 30 h, and 48 h after administration of the test item.
Since no gender specific differences on acute toxic symptoms were observed in agreement with the sponsor the main study was performed using males only.
Dose Selection
It is generally recommended to use the maximum tolerated dose or the highest dose that can be formulated and administered reproducibly or 2000 mg/kg as the upper limit for non-toxic test items.
The maximum tolerated dose level is determined to be the dose that causes toxic reactions without having major effects on survival within 48 hours.
The administered volume was 10 mL/kg b.w..
Three adequately spaced dose levels spaced by a factor of 2 were administered, and samples were collected at the central sampling interval 24 h after treatment. For the highest dose level an additional sample was taken at 48 h after treatment.
Pre-Experiments for Toxicity
The animals treated in the pre-experiments received the test item 4-phenylbutenone dissolved in 30% DMSO / 70% PEG 400 once orally. The volume administered was 10 mL/kg b.w.. The following dose levels were tested and expressed toxic reactions were shown in the table:
Table 1: results of the pre-experiments for toxicity
| hours post-treatment | |||||
| 1 | 2-4 | 6 | 24 | 30 | 48 |
1stPre-experiment: 1000 mg/kg b.w. ; males / females | ||||||
reduction of spontaneous activity | 0/0 | 0/2 | 0/2 | 0/2 | 0/2 | 0/0 |
ruffled fur | 0/0 | 0/2 | 0/2 | 0/2 | 0/2 | 0/0 |
On the basis of these data 2000 mg/kg b.w. were estimated to be suitable as highest dose.
No substantial sex specific differences were observed with regard to clinical signs. In agreement with the sponsor the main study was performed using males only.
Toxic Symptoms in the Main Experiment
In the main experiment for each test item dose groups 7 males received the test item 4-phenylbutenone dissolved in 30% DMSO / 70% PEG 400 once orally. The volume administered was 10 mL/kg b.w.. The symptoms of toxicity observed following treatment are shown in the following table for each dose group, which indicates the number of males with findings. The animals treated with the negative control (30% DMSO / 70% PEG 400) did not express any toxic reaction.
Table 2: Toxic symptoms in the main experiment
| hours post-treatment (males) | ||||
| 1 | 2-4 | 6 | 24 | 48* h |
High dose: 2000 mg/kg b.w. (24 h and 48 h) | |||||
reduction of spontaneous activity | 3 | 4 | 4 | 2 | 0 |
abdominal position | 3 | 1 | 1 | 0 | 0 |
eyelid closure | 3 | 2 | 2 | 2 | 0 |
ruffled fur | 3 | 3 | 3 | 4 | 0 |
death | 0 | 1** | 0 | 0 | 0 |
Medium dose: 1000 mg/kg b.w. (24 h) | |||||
reduction of spontaneous activity | 1 | 1 | 1 | 0 | - |
abdominal position | 1 | 0 | 0 | 0 | - |
eyelid closure | 1 | 1 | 1 | 0 | - |
ruffled fur | 1 | 1 | 1 | 1 | - |
Low dose: 500 mg/kg b.w. (24 h) | |||||
abdominal position | 3 | 0 | 0 | 0 | - |
eyelid closure | 4 | 0 | 0 | 0 | - |
excitement | 2 | 0 | 0 | 0 |
|
ruffled fur | 4 | 0 | 0 | 0 | - |
* data only from 7 male animals
** animal no. 40
- no observation made
Table 3: Summary of Micronucleus Test Results
test group | dose mg/kg b.w. | sampling time (h) | PCEs with micronuclei (%) | range | PCE per 2000 erythrocytes |
vehicle | 0 | 24 | 0.050 | 0 -2 | 1288 |
test item | 500 | 24 | 0.114 | 0 -3 | 1333 |
test item | 1000 | 24 | 0.100 | 0 -5 | 1245 |
test item | 2000 | 24 | 0.093 | 1 -3 | 1234 |
positive control | 40 | 24 | 1.964 | 32 -49 | 1240 |
test item | 2000 | 48 | 0.042 | 0 -2 | 1099 |
Applicant's summary and conclusion
- Conclusions:
- The in vivo micronucleus test was conducted in NMRI mice, according to OECD 474 and EU Method B12 (with only non-significant deviations) and therefore considered to be of the highest quality. No increases in the incidence of micronucleated PCEs were observed in males exposed to 4-phenylbutenone. It is therefore considered that 4-phenylbutenone is not clastogenic (negative) in the mouse micronucleus test.
- Executive summary:
The test item 4-phenylbutenone was assessed in the micronucleus assay for its potential to induce micronuclei in polychromatic erythrocytes (PCE) in the bone marrow of the mouse (Roth, 2012). The test item was dissolved in 30% DMSO / 70% PEG 400, which was also used as vehicle control. The volume administered orally was 10 mL/kg b.w. and 24 h and 48 h after a single administration of the test item the bone marrow cells were collected for micronuclei analysis. Seven males per test group were evaluated for the occurrence of micronuclei. Per animal 2000 polychromatic erythrocytes (PCEs) were scored for micronuclei. To describe a cytotoxic effect due to the treatment with the test item the ratio between polychromatic and normochromatic erythrocytes was determined in the same sample and reported as the number of PCEs per 2000 erythrocytes.
As estimated by pre-experiments 2000 mg 4-phenylbutenone per kg bw was suitable as top dose. The following dose levels of the test item were investigated: 24 h preparation interval: 500, 1000, and 2000 mg/kg bw and 48 h preparation interval: 2000 mg/kg bw.
As a result , the mean number of polychromatic erythrocytes was not substantially decreased after treatment with the test item as compared to the mean value of PCEs of the vehicle control indicating that 4-phenylbutenone did not have any cytotoxic properties in the bone marrow. However, one male (animal no. 40) of the high dose group (48 h treatment interval) died approximately 3 hours after treatment with the test item.
In comparison to the corresponding vehicle controls there was no statistically significant or biologically relevant enhancement in the frequency of the detected micronuclei at any preparation interval and dose level after administration of the test item. The mean values of micronuclei observed after treatment with 4-phenylbutenone were near to the value of the vehicle control group. However, the statistically significant increase above the vehicle control group observed in the low dose group was considered to have no biological relevance, as the value was well within the laboratory’s historical vehicle control data. Additionally, no dose dependent increase in the frequency of detected micronuclei was observed with increasing dosages.
Cyclophosphamide administered once orally (40 mg/kg b.w.) was used as positive control which showed a substantial and biologically relevant increase of induced micronucleus frequency.
In conclusion, it can be stated that during the study described and under the experimental conditions reported, the test item did not induce micronuclei as determined by the micronucleus test in the bone marrow cells of the mouse. Therefore, 4-phenylbutenone is considered to be non-mutagenic (negative) in this micronucleus assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live2